You are leaving Lundbeck.com/US
You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit.
Pipeline
Therapies in development
Our research and development teams aim to target the underlying mechanisms of brain disease. We move together towards a singular goal to deliver novel therapies that redefine the standard of care for patients and address the areas in brain disease where we see the greatest need.
Hormonal / neuropeptide signaling
| Project | Area | Phase 1 | Phase 2 | Phase 3 | Filing | ||
|---|---|---|---|---|---|---|---|
| Eptinezumab (anti-CGRP mAb)¹ | Migraine prevention² | Filing | |||||
| Eptinezumab (anti-CGRP mAb)¹ | Cluster headache | 3 | |||||
| Lu AG09222 (anti-PACAP mAb)³ | Migraine prevention² | 2 | |||||
| Lu AG13909 (anti-ACTH mAb)⁴ | Neurohormonal dysfunctions | 1 |
Circuitry / neuronal biology
| Project | Area | Phase 1 | Phase 2 | Phase 3 | Filing | ||
|---|---|---|---|---|---|---|---|
| Brexpiprazole⁵ | PTSD⁶ | Filing | |||||
| Lu AF28996 (D1-D2 agonist)⁷ | Parkinson's disease | 1 | |||||
| MAGLi program⁸ | Neurology | 1 | |||||
| Bexicaserin (5HT2C agonist) | Developmental and epileptic encephalopathies | 3 |
Protein aggregation, folding and clearance
| Project | Area | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|
| Amlenetug (anti α-synuclein mAb) | Synucleinopathies (MSA) | 3 |
Neuroinflammation / Neuroimmunology
| Project | Area | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|
| Lu AG22515 (CD40L blocker)⁹ | Neurology | 1 |
More from Lundbeck
Research and Development
R&D of new and improved treatments is at the core of what we do.
Partnering
Partnerships are a key pillar in our strategy to become leaders in brain health.